Xylometazoline
- Generic Name
- Xylometazoline
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C16H24N2
- CAS Number
- 526-36-3
- Unique Ingredient Identifier
- WPY40FTH8K
- Background
Xylometazoline is an imidazoline derivative with sympathomimetic and nasal decongestant activity. Xylometazoline works by binding to alpha (α)-adrenergic receptors to cause vasoconstriction of nasal blood vessels.
Xylometazoline is available in over-the-counter (OTC) nasal sprays or drops to temporarily relieve nasal congestion due to cold, hay fever or other respiratory allergies. In some countries, it is available as combination products with ipratropium, domiphen, or dexpanthenol.
- Indication
Xylometazoline is indicated for the temporary relief of nasal congestion due to cold, hay fever or other respiratory allergies.
- Associated Conditions
- Allergic Rhinitis (AR), Nasal Congestion, Seasonal Allergic Rhinitis
- Associated Therapies
- -
Xylometazoline During Nasal Flexible Bronchoscopy
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2019-03-11
- Target Recruit Count
- 148
- Registration Number
- NCT03424889
- Locations
- 🇮🇳
AIIMS, New Delhi, India
The Role of the Nose in Snoring and Sleep Apnea
- Conditions
- Interventions
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Lovisenberg Diakonale Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03072173
- Locations
- 🇳🇴
Lovisenberg Diaconal Hospital, Oslo, Norway
Nasal Decongestion and Obstructive Sleep Apnea
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 12
- Registration Number
- NCT00630474
- Locations
- 🇨🇭
Pulmonary Division, University Hospital Zurich, Zurich, Switzerland
🇨🇭Pulmonary Division, University Hospital Zurich, Switzerland, Zurich, Switzerland
Decongestant Effect, Timing of Effect and Impact on Sleep and General Well-Being of Xylometazoline in Subjects With a Common Cold
- Conditions
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2007-05-03
- Lead Sponsor
- Novartis
- Target Recruit Count
- 60
- Registration Number
- NCT00452270
- Locations
- 🇬🇧
Novartis Investigative Site, Cardiff, Wales, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.